First clinical experience with single-photon emission computed tomography with technetium-99m-labeled prostate-specific membrane antigen at the Chelyabinsk Regional Clinical Center of Oncology and Nuclear Medicine

Cover Page

Cite item

Full Text

Open Access Open Access
Restricted Access Access granted
Restricted Access Subscription or Fee Access

Abstract

Background: Positron emission tomography combined with computed tomography (PET/CT) using prostate-specific membrane antigen (PSMA)-based radiopharmaceuticals is widely used in the management of patients with prostate cancer. However, this method may be unavailable in some regions due to the lack of a positron emission tomography (PET) scanner. Therefore, a new method may be used: single-photon emission computed tomography combined with computed tomography (SPECT/CT) using technetium-99m-labeled PSMA (99mTc-PSMA).

Objective: Evaluation of the clinical application of SPECT-CT with 99mTc-PSMA in patients with prostate cancer.

Materials and methods: The study was conducted at the Department of Radionuclide Diagnostics, Chelyabinsk Regional Clinical Center of Oncology and Nuclear Medicine. The study included four patients with prostate cancer, aged 55–80 years, with biochemical recurrence: prostate-specific antigen (PSA) 16.2 ng/ml, PSA 50.58 ng/ml, PSA 4.24 ng/ml, and PSA 17.2 ng/ml. All patients underwent planar imaging followed by SPECT/CT of the region of interest.

Results: The study results indicate that this method is informative in visualizing local recurrences and/or metastases, and can also be used to assess the extent of the disease.

Conclusion: SPECT/CT with 99mTc-PSMA in patients with biochemical recurrence revealed tumor invasion into surrounding tissue in two patients and metastatic disease in all subjects.

About the authors

Anastasia Y. Aniskova

Chelyabinsk Regional Clinical Center of Oncology and Nuclear Medicine

Author for correspondence.
Email: mau8aaa@mail.ru
ORCID iD: 0009-0004-7285-6040

Radiologist, Department of Radionuclide Diagnostics

Russian Federation, Chelyabinsk

N. G. Afanas’eva

Chelyabinsk Regional Clinical Center of Oncology and Nuclear Medicine

Email: mau8aaa@mail.ru
ORCID iD: 0000-0002-9432-5396
Russian Federation, Chelyabinsk

References

  1. Клинические рекомендации. Рак предстательной железы 2023 г. [Clinical guidelines Prostate cancer 2023.(In Russ.)].
  2. Злокачественные новообразования в России в 2023 году (заболеваемость и смертность). Под ред. А.Д. Каприна, В.В. Старинского, А.О. Шахзадовой. М.: МНИОИ им. П.А. Герцена – филиал ФГБУ «НМИЦ радиологии» Минздрава России, 2024. 276 с. [Malignant tumors in Russia in 2023 (morbidity and mortality). Eds.: А.D. Kaprin, V.V. Starinskiy, A.O Shachzadova. Moscow, 2024. 276 p. (In Russ.)].
  3. Israeli R.S., Powell C.T., Fair W.R., Heston W.D. Molecular cloning of a comple-mentary DNA encoding a prostate-specific membrane antigen. Cancer Res. 1993;53(2):227–320.
  4. Silver D.A., Pellicer I., Fair W.R., et al. Prostate-specific membrane antigen expression in normal and malignant human tissues. Clin Cancer Res. 1997;3(1):81–85.
  5. Леонтьев А.В., Халимон А.И., Кулиев М.Т. и др. Современные возможности применения радиофармпрепаратов на основе лигандов к простатспецифическому мембранному антигену, меченных 99mTc, при раке предстательной железы. Онкоурология. 2021;17(4):136–150. [Leontiev A.V., Halimon A.I., Kuliyev M.T., et al. Modern possibilities of using radiopharmaceuticals based on prostate-specific membrane antigen ligands labeled with 99mTc in prostate cancer. Onkourologiya = Cancer Urology 2021;17(4):136–150. (In Russ.)]. https://doi.org/10.17650/1726-9776-2021-17-4-136-150
  6. Носов Д.А., Волкова М.И., Гладков О.А. и др. Практические рекомендации по лекарственному лечению рака предстательной железы. Злокачественные опухоли: Практические рекомендации RUSSCO. 2020;10(3s2):556-572. [Nosov D.A., Volkova M.I., Gladkov O.A., et al. Practical recommendations for the medical treatment of prostate cancer. Malignant tumors: practical recommendations RUSSCO. 2020;10(3s2):556-572. (In Russ.)].
  7. Hupe M.C., Philippi C., Roth D., et al. Expression of prostate-specific membrane antigen (PSMA) on biopsies is an independent risk stratifier of prostate cancer patients at time of initial diagnosis. Front Oncol. 2018;8:623. https://doi.org/10.3389/fonc.2018.00623
  8. Oliveira J.M., Gomez S., Faria D.B., et al. Positron emission tomography/ computed tomography of Ga-specific prostate membrane antigen for prostate cancer imaging: a review of the descriptive literature. World J Nucl Med. 2017;16(1):3-7. https://doi.org/10.4103/1450-1147.198237
  9. Maurer T., Eiber M., Schwaiger M., Gschwend J.E. Current use of PSMA-PET in prostate cancer management. Nature Reviews. Urology. 2016;13:226–235. https://doi.org/10.1038/nrurol.2016.26
  10. Afshar-Oromieh A., Haberkorn U., Schlemmer H.P., et al. Comparison of PET imaging with a 68Ga-labelled PSMA ligand and 18F-choline-based PET/CT for the diagnosis of recurrent prostate cancer. Eur J Nucl Med Mol Imaging. 2014;41(1):11–20. https://doi.org/10.1007/s00259-013-2525-5
  11. Schmidkonts C., Hollweg C., Beck M., et al. Tc-MIP-1404 is a SPECT-CT scan for the detection of PSMA-positive lesions in 225 patients with biochemical recurrence of prostate cancer. Prostate. 2018;78(1):54–63. https://doi.org/10.1002/pros.23444
  12. Sergieva S., Mangaldgiev R., Dimcheva M., et al. SPECT-CT imaging with [99mTc]PSMA-T4 in patients with recurrent prostate cancer. Nucl Med Rev Cent East Eur. 2021;24(2):70-81. https://doi.org/10.5603/NMR.2021.0018
  13. Велиев Е.И., Томилов А.А., Гончарук Д.А. и др. Диагностические возможности ПЭТ/КТ 68GA-PSMA для пациентов с рецидивом рака предстательной железы. Урология. 2018;3:105–110. [Veliyev E.I., Tomilov A.A., Goncharuk D.A., et al. Golubtsovadiagnostic capabilities of 68GA-PSMA PET/CT for patients with recurrent prostate cancer. Urology. 2018;3:105–110. (In Russ.)]. https://dx.doi.org/10.18565/urology.2018.2.105-110
  14. Медведева А.А., Чернов В.И., Усынин Е.А. и др. Использование 177lu-псма для радионуклидной терапии у пациентов с кастрационно-резистентным раком предстательной железы. Сибирский онкологический журнал. 2021;20(3):115–123. [Medvedeva A.A., Chernov V.I., Usynin E.A., et al. Тhe use of 177lu-psma for radionuclide therapy in patients with castration-resistant prostate cancer Siberian Oncological Journal. 2021;20(3):115–123. (In Russ.)]. https://doi.org/10.21294/1814-4861-2021-20-3-115-123
  15. Li B., Duan L., Shi J., et al. Diagnostic performance of 99mTc-HYNIC-PSMA SPECT/CT for biochemically recurrent prostate cancer after radical prostatectomy. Front Oncol. 2022;12:1072437. https://doi.org/10.3389/fonc.2022.1072437

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

Copyright (c) 2026 Bionika Media

License URL: https://journals.eco-vector.com/2073-4034/about/editorialPolicies